MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
3.940
-0.090
-2.23%
After Hours: 3.950 +0.01 +0.25% 17:41 07/07 EDT
OPEN
4.030
PREV CLOSE
4.030
HIGH
4.085
LOW
3.860
VOLUME
528.25K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.350
MARKET CAP
371.62M
P/E (TTM)
-0.8593
1D
5D
1M
3M
1Y
5Y
1D
X4 Pharmaceuticals issues inducement stock options for 750,000 shares at $4.03 each
PUBT · 10h ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 15h ago
Weekly Report: what happened at XFOR last week (0629-0703)?
Weekly Report · 1d ago
CFO’s Bold Move at X4 Pharmaceuticals Shakes Up Investor Buzz
TipRanks · 6d ago
X4 Pharmaceuticals Expands Board with New Independent Director
TipRanks · 6d ago
X4 Pharmaceuticals director Kelly Gold files initial beneficial ownership statement
PUBT · 6d ago
X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board
TipRanks · 6d ago
X4 Pharmaceuticals appoints CAMP4 CFO Kelly Gold to board, audit committee
PUBT · 6d ago
More
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.